Biotinylated Human IL-17C, His,Avitag (ILC-H82E5) is expressed from human 293 cells (HEK293). It contains AA His 19 - Val 197 (Accession # Q9P0M4-1).
Predicted N-terminus: His 19
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag.
The protein has a calculated MW of 23.4 kDa. The protein migrates as 25-28 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
The biotin to protein ratio is 0.5-1 as determined by the HABA assay.
Less than 1.0 EU per μg by the LAL method.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Biotinylated Human IL-17C, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Human IL-17 RE (155-454), Fc Tag (Cat. No. ILE-H5256) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-17C, His,Avitag (Cat. No. ILC-H82E5) with a linear range of 0.5-13 ng/mL (QC tested).
Interleukin-17C(IL-17C) is a glycosylated cytokine that plays an important role in mucosal immunity and chronic inflammation. IL‑17C binds to IL‑17 RE with high affinity and to IL‑17 RA with low affinity, binds to a heterodimer formed by IL17RA and IL17RE. Enhanced IL17C/IL17RE signaling may also lead to greater susceptibility to autoimmune diseases. Stimulates the production of antibacterial peptides and proinflammatory molecules for host defense by signaling through the NF-kappa-B and MAPK pathways. Acts synergically with IL22 in inducing the expression of antibacterial peptides, including S100A8, S100A9, REG3A and REG3G. Synergy is also observed with TNF and IL1B in inducing DEFB2 from keratinocytes.